This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
26 Sep 2011

Merck Opens R&D Facility in Ireland

Six drugs are currently in development at the facility, including Merck's candidate drug for the treatment of hepatitis C and a dual high cholesterol/type II diabetes medication.

US-based pharmaceutical company Merck has launched a €100m R&D facility in Ireland.

 

The facility at Ballydine, Co Tipperary will house 70 new R&D roles, with the capacity to expand to 120 should new innovative medicines be developed. An additional investment of €6m is already planned to cater for the extra capacity.

 

Six drugs are currently in development at the facility, including Merck's candidate drug for the treatment of hepatitis C and a dual high cholesterol/type II diabetes medication. Three of Merck's five top priority candidate medicine research programmes are now based at the facility.

 

Ballyd

Related News